unresectable pancreatic cancer
Conditions
Interventions
standard chemotherapy (GEM/nab-PTX) with WT1 peptides pulsed dendritic cells (WT1-DC) The WT1-DC vaccine (usually 1 X10^7 cells/dose) was intradermally administered once every 2 or 4 weeks at six d
Sponsors
The Jikei University School of Medicine, Kashiwa Hospital, Division of Gastroenterology & Hepatology, Department of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) pathologically or cytologically confirmed, measurable, metastatic pancreatic adenocarcinoma or with recurrent disease 2) an HLA type of A*02:01, A*02:06, A*24:02, DRB1*04:05, DRB1*08:03, DRB1*15:01, DRB1*15:02, DPB1*05:01, or DPB1*09:01.3) 3) ages between 20 and 75 years 4) Karnofsky performance status (KPS) of 60% to 100% 5) a minimum 6-month interval from the completion of any previous treatment for recurrent disease 6) a life expectancy of 3 months 7) adequate organ function etc
Exclusion criteria
Exclusion criteria: 1) pregnancy 2) serious infections 3) severe underlying disease 4) severe allergic disease 5) a judgment of unsuitability by the principal investigator etc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety and toxicity | — |
Secondary
| Measure | Time frame |
|---|---|
| the assessment of the immunologic response, tumor response, overall survival (OS), and progression-free survival (PFS) from the first treatment | — |
Countries
Japan
Contacts
Public ContactShigeo Koido
The Jikei University School of Medicine, Kashiwa Hospital Division of Gastroenterology & Hepatology, Department of Internal Medicine
Outcome results
None listed